Home › Calculator › ARWR Dividend Calculator 2026
ARWR Dividend DRIP Calculator 2026
2.42% YieldHealthcareArrowhead Pharmaceuticals, Inc. · NASDAQ
Price: $82.63 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ARWR pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ARWR snowball 📈
$10,000 in ARWR → $10.49M in 10 years · $20.66/month
About Arrowhead Pharmaceuticals, Inc. (ARWR) — Dividend Analysis 2026
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Compare ARWR with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ARWR DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ARWR position with:
🌍 ARWR Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ARWR.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.42% | -0.38% | $242 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.06% | -0.74% | $206 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.94% | -0.86% | $194 / yr |
| 🇬🇧 UK ISA | 0% | 2.42% | -0.38% | $242 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.21% | -0.59% | $221 / yr |
| 🇨🇦 TFSA | 0% | 2.42% | -0.38% | $242 / yr |
| 🇨🇦 CA Taxable | 25% | 1.81% | -0.98% | $182 / yr |
| 🇦🇺 Super (pension) | 15% | 2.06% | -0.74% | $206 / yr |
| 🇦🇺 AU Taxable | 30% | 1.69% | -1.11% | $169 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.78% | -1.02% | $178 / yr |
| 🇫🇷 FR Taxable | 30% | 1.69% | -1.11% | $169 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ARWR Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ARWR Dividend Payment Schedule
ARWR pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ARWR vs Healthcare Benchmarks
How ARWR compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ARWR sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ARWR Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-08-18 | 2,000 | $86.96 | $173.9K | ||
| Sale | 2026-08-18 | 11,600 | $87.30 | $1.01M | ||
| A-Award | 2026-06-15 | 11,882 | — | — | ||
| Sale | 2026-05-12 | 2,970 | $76.88 | $228.3K | ||
| Sale | 2026-04-22 | 3,208 | $70.11 | $224.9K | ||
| Sale | 2026-04-22 | 1,157 | $70.45 | $81.5K | ||
| Sale | 2026-04-22 | 8,730 | $71.92 | $627.9K | ||
| Sale | 2026-04-23 | 10,000 | $75.00 | $750.0K | ||
| Sale | 2026-03-05 | 10,000 | $64.19 | $641.9K | ||
| A-Award | 2026-01-06 | 75,000 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ARWR dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $82.63, trading near its 52-week high. The current dividend yield is 2.42% based on an annual payout of $2.00 per share.
ARWR (Arrowhead Pharmaceuticals, Inc.) — 2.42% Dividend Yield Analysis
Arrowhead Pharmaceuticals, Inc. (ARWR) is a healthcare stock currently trading at $82.63 with a dividend yield of 2.42%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.